Improving treatments for neuroblastoma means understanding its complexity

A recent study has been looking at the outcomes for children with relapsed neuroblastoma in the UK over the past 20 years in an attempt to understand how better to treat these children.

Professor Deb Tweddle, lead author of the study, believes “...it’s essential that doctors and researchers focus on the underlying biology of the disease... Once we master the complexity of the disease we can begin to personalise treatment for each child.” 

The study highlights how patients with relapsed neuroblastoma are being managed today, providing a baseline for which new therapies can be measured.

Read CRUK’s blog for more on the report.